Bioscience firm makes progress on another kind of vaccine

The word vaccine carries heavy weight these days, with its tantalizing possibilities to curb the destruction brought on by a certain C-word.

But at Tampa-based bioscience company Morphogenesis, the word vaccine is connected to a different kind of C-word: cancer. And the company, backed by nearly $30 million and the support of board Chairman Dr. Kiran Patel, a leading area philanthropist, is zeroing in on some major milestones in its cancer vaccination effort. The list includes a new manufacturing facility, expanded clinical trials and a potential new capital raise, with its eye on a possible public offering.